Heska Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HSKA research report →
Range $149 – $170
Price Chart
About the company
Heska Corporation provides specialized diagnostic and animal health products, predominantly for canine and feline veterinary care markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. Its product line includes a variety of veterinary chemistry analyzers: the Element DC, DCX, and DC5x series, along with the Element RC, RCX, and RC3X systems, all tailored for blood chemistry and electrolyte analysis. For hematological assessments, Heska offers the Element HT5 and scil Vet abc Plus analyzers, capable of measuring blood cell and platelet counts, as well as hemoglobin levels.
- CEO
- Kevin S. Wilson
- IPO
- 1997
- Employees
- 808
- HQ
- Loveland, CO, US
Get TickerSpark's AI analysis on HSKA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.31B
- P/E
- -67.41
- PEG
- 1.58
- P/S
- 5.09
- P/B
- 2.94
- EV/EBITDA
- -61.88
- Div Yield
- 0.00%
- Gross Margin
- 43.20%
- Op Margin
- -7.89%
- Net Margin
- -7.16%
- ROE
- -4.29%
- ROIC
- -3.12%
Latest fiscal year · YoY change
- Revenue
- $257.31M+1.4%
- Gross Profit
- $111.17M+5.1%
- Op Income
- $-20,298,000
- Net Income
- $-18,424,000-14057.6%
- EPS
- $-1.78-13584.8%
- OCF Growth
- -449.2%
- FCF Growth
- -634.2%
- 52W High
- $120.03
- 52W Low
- $57.83
- 50D MA
- $117.59
- 200D MA
- $87.26
- Beta
- 1.60
- RSI (14)
- 75
- Avg Volume
- 336.67K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Heska said 2022 ended with stronger margins and subscription momentum, and management sounded upbeat on 2023 growth drivers including Element AIM, Nu.Q, and LightDeck integration.· February 28, 2023
- Q4 revenue was $66.3 million and full-year 2022 revenue was $257.3 million, with reported annual revenue up 5.4% after adjusting for about $10 million of FX headwinds.
- Consolidated gross margin improved to 41.9% in Q4 and 43.2% for the full year, helped by higher subscriptions and better mix.
- 2023 revenue guidance is $278 million to $288 million, implying 8% to 12% growth, with gross margin expected to expand 100 to 200 bps before LightDeck.
- Management expects about 400 Element AIM analyzer placements in 2023 and said Nu.Q is a contributor to consumable growth, but not a major near-term guide item.
- LightDeck closed on January 3 using about $22 million in cash, and management said it will pressure adjusted EBITDA margin back to around 10% in 2023.
Heska reported fourth-quarter revenue of $66.3 million and full-year 2022 revenue of $257.3 million. Reported annual revenue grew 5.4% after adjusting for about $10 million of currency headwinds; excluding FX, international segment revenue grew 2.8% in Q4 and 10.9% for the full year. Consolidated gross margin improved by about 100 basis points to 41.9% in Q4 and 150 basis points to 43.2% for the full year; adjusted EBITDA was $6.2 million in Q4 (margin 9.4%) and $27.2 million for the full year (margin 10.6%). Looking ahead, 2023 revenue is guided to $278 million to $288 million, with POC Lab revenue of $165 million to $175 million, POC Imaging revenue of $60 million to $70 million, gross margin expansion of 100 to 200 bps before LightDeck, and adjusted EBITDA margin expected to expand 100 to 200 bps before LightDeck, but remain around 10% including LightDeck.
Kevin Wilson struck an upbeat tone, saying the company had a “great release” and that 2022 work created momentum for 2023. He emphasized market-share gains, improved gross margin, subscription growth, and the commercialization of differentiated products like Element AIM, Nu.Q, and the new rapid-test and software pipeline. He also framed 2023 as the transition from a long build phase into a “win at scale and win at innovation” phase.
Catherine Grassman focused on the drivers behind revenue and margin improvement. She cited North America subscription growth, Element AIM placements, and about 9% consumables growth, while international benefited from VetZ and the reset program; gross margin expanded to 41.9% in Q4 and 43.2% for the year, and adjusted EBITDA reached $6.2 million in Q4 and $27.2 million for 2022. For 2023, she guided to $278 million to $288 million in revenue, gross margin expansion of 100 to 200 bps before LightDeck, about $157 million of cash at year-end before the LightDeck cash use, and about $60 million to $70 million of total capital use including LightDeck-related operations and other investments.
Analysts pressed on international growth, North America pricing, vet visit trends, Element AIM placement cadence, and Nu.Q contribution. Management said Europe should benefit from price increases, easier subscription comps, better execution on trūRapid launches, and product rationalization; in North America they expect price to contribute about 7% to 8% and see vet visits normalizing with improvement in the back half of 2023. On AIM, Kevin said fourth-quarter activity showed the full sales cycle working and that over 40 analyzers in December gave them confidence in the 400-unit 2023 target; on Nu.Q, Catherine said it is a contributor to consumable growth but not a major part of the 2023 guide.
The call pointed to improving gross margins, stronger subscription economics, and multiple product catalysts that management believes can support share gains in 2023. Management sounded confident that pricing, easier comps, and better execution in Europe and on new launches could help revenue accelerate later in the year.
Management still sees macro pressure, especially in European vet visits and in capital sales of imaging-related products, and acknowledged that Nu.Q is not yet a major 2023 revenue driver. LightDeck also adds cash usage and is expected to keep adjusted EBITDA margin around 10%, which tempers some of the operating leverage from the core business.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 94.3%
- Shares Outstanding
- 10.91M
- Float Shares
- 10.29M
of shares held by institutions
152 13F filers
Buy/sell ratio 0.37. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Monarch Partners Asset Management LLC | 25.89K | ▼ 18.37K |
| Parametric Portfolio Associates LLC | 17.58K | ▲ 1.08K |
| Amalgamated Financial Corp. | 5.12K | ▲ 5.12K |
| Wipfli Financial Advisors LLC, | 50 | ▲ 50 |
| Private Capital Group, LLC | 27 | 0 |
| American Portfolios Advisors | 14 | 0 |
Held by 4 ETFs
Biggest fund positions in HSKA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 13, 23 | Davis Stephen L | sell | 500 |
| Jun 13, 23 | Hasenmaier Joachim A. | sell | 2,004 |
| Jun 13, 23 | Eyl Steven M. | other | 4,056 |
| Jun 13, 23 | Eyl Steven M. | other | 33,111 |
| Feb 28, 22 | Eyl Steven M. | other | 20,000 |
| Jun 13, 23 | Eyl Steven M. | sell | 1,146 |
| Jun 13, 23 | Eyl Steven M. | sell | 3,041 |
| Jun 13, 23 | Eyl Steven M. | sell | 1,918 |
| Jun 13, 23 | Eyl Steven M. | sell | 1,372 |
| Jun 13, 23 | Eyl Steven M. | sell | 7,691 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HSKA coverage
Recent articles, reports, and earnings notes.
No research on HSKA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HSKA report →Dalan Animal Health Ships First Honey Bee Vaccine to Tauzer Apiaries, Potentially Protecting 25 Million Bees.
businesswire.com · May 23
HESKA CORPORATION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Heska Corporation - HSKA
businesswire.com · May 10
Heska (HSKA) Q1 Earnings and Revenues Lag Estimates
zacks.com · May 5
HESKA CORPORATION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Heska Corporation - HSKA
businesswire.com · Apr 4
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HSKA, LSI, EXR, DFFN
prnewswire.com · Apr 3
Why Heska Stock Is On Fire Today
fool.com · Apr 3
HSKA STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Heska Corporation Is Fair to Shareholders
businesswire.com · Apr 3
Heska Corporation (HSKA) Q4 2022 Earnings Call Transcript
seekingalpha.com · Feb 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.